Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment
- PMID: 1425066
- DOI: 10.1007/BF01299859
Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment
Abstract
The increased risk of gallstone formation in acromegalics treated with the somatostatin analog octreotide has been related to an impaired gallbladder emptying. To determine the duration of these inhibitory effects, meal-stimulated gallbladder motility, plasma cholecystokinin (CCK), and pancreatic polypeptide (PP) were measured in five acromegalics treated for 6-32 months with 200-300 micrograms octreotide daily. Meal tests were performed 45 min, 8 hr and two weeks after the last 100-micrograms subcutaneous dose. Results were compared with those in normal subjects. Integrated postprandial gallbladder contraction (-125 +/- 194 cm3/120 min) and integrated PP secretion (-0.1 +/- 0.2 nmol/liter/120 min) were completely suppressed in the 45-min study, but significantly improved (P < 0.05) when measured 8 hr (1376 +/- 322 cm3/120 min and 3.0 +/- 1.0 nmol/liter/120 min) and two weeks (1437 +/- 263 cm3/120 min and 10.6 +/- 1.6 nmol/liter/120 min) after the last dose of octreotide. The integrated gallbladder contraction in acromegalics at 8 hr was comparable to that at two weeks and to that in normal subjects, but the integrated PP response at 8 hr was significantly smaller (P < 0.05 vs two weeks and vs normals). Integrated plasma CCK secretion at 45 min (0.13 +/- 0.06 nmol/liter/120 min) was not statistically significantly different from the response at 8 hr (0.15 +/- 0.02 nmol/liter/120 min) and from that in normal subjects, but it was significantly increased at two weeks after cessation of octreotide (P < 0.05 vs 45 min and 8 hr).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.Gut. 1993 Jun;34(6):808-13. doi: 10.1136/gut.34.6.808. Gut. 1993. PMID: 8314514 Free PMC article.
-
Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly.J Clin Endocrinol Metab. 1989 Sep;69(3):557-62. doi: 10.1210/jcem-69-3-557. J Clin Endocrinol Metab. 1989. PMID: 2760170 Clinical Trial.
-
Postprandial release of cholecystokinin and pancreatic polypeptide in health and in gallstone disease: relationships with gallbladder contraction.Am J Gastroenterol. 1994 Mar;89(3):404-10. Am J Gastroenterol. 1994. PMID: 8122654
-
Pancreatic exocrine and gallbladder function during long-term treatment with octreotide (SMS 201-995).Digestion. 1990;45 Suppl 1:72-6. doi: 10.1159/000200266. Digestion. 1990. PMID: 2185969 Review.
-
Gallstones during octreotide therapy.Metabolism. 1992 Sep;41(9 Suppl 2):22-33. doi: 10.1016/0026-0495(92)90027-8. Metabolism. 1992. PMID: 1355588 Review.
Cited by
-
Increased gall bladder volume in primary sclerosing cholangitis.Gut. 1996 Oct;39(4):594-9. doi: 10.1136/gut.39.4.594. Gut. 1996. PMID: 8944571 Free PMC article.
-
Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.Gut. 1996 May;38(5):775-83. doi: 10.1136/gut.38.5.775. Gut. 1996. PMID: 8707128 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous